Spyre Therapeutics, Inc. (SYRE)
| Market Cap | 7.85B +700.3% |
| Revenue (ttm) | n/a |
| Net Income | -150.21M |
| EPS | -2.01 |
| Shares Out | 88.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,096,049 |
| Open | 88.64 |
| Previous Close | 84.72 |
| Day's Range | 88.00 - 95.08 |
| 52-Week Range | 15.82 - 110.18 |
| Beta | 3.11 |
| Analysts | Strong Buy |
| Price Target | 120.08 (+34.88%) |
| Est. Earnings | Nov 3, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $120.08, which is an increase of 34.88% from the latest price.
News
Spyre Therapeutics rises 6.8%
Spyre Therapeutics (SYRE) is up 6.8%, or $5.72 to $90.44.
Spyre Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
The forum highlighted a strategy centered on best-in-class, long-acting antibody combinations for autoimmune diseases, with IBD as the lead indication. SKYLINE study results next year will guide advancement in both UC and Crohn's, while promising data in HS and rheumatology support further expansion.
Spyre Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Focused on advancing optimized biologic combinations for autoimmune diseases, the company is running a global, near-phase III scale trial in IBD, with monotherapy and combination arms. Long-acting antibodies show efficacy and dosing advantages, and upcoming readouts in IBD, HS, and other indications will guide phase III priorities. Strong financials support multiple late-stage programs.
Spyre Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
The company is advancing best-in-class antibody therapies for autoimmune diseases, with a focus on IBD and expansion into rheumatic and dermatologic indications. Strong recent data, a robust financial position, and a differentiated co-formulation strategy support multiple upcoming readouts and potential market leadership.
Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial
Spyre Therapeutics (SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely act...
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation th...
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the st...
Spyre Therapeutics falls -13.2%
Spyre Therapeutics (SYRE) is down -13.2%, or -$14.16 to $93.20.
Spyre Therapeutics falls -11.6%
Spyre Therapeutics (SYRE) is down -11.6%, or -$12.47 to $94.89.
Spyre Therapeutics price target lowered to $123 from $130 at Wedbush
Wedbush lowered the firm’s price target on Spyre Therapeutics (SYRE) to $123 from $130 and keeps an Outperform rating on the shares. The firm notes the company reported topline Phase…
Spyre Therapeutics price target lowered to $121 from $132 at BTIG
BTIG lowered the firm’s price target on Spyre Therapeutics (SYRE) to $121 from $132 and keeps a Buy rating on the shares. The firm cites the company’s findings on SPY072,…
Spyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Spyre Therapeutics (SYRE) to $127 from $135 and keeps a Buy rating on the shares following the topline results from the rheumatoid…
Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors
Spyre Therapeutics ($SYRE) fell as much as 14% in after‑hours trading on Tuesday after the company said it will stop developing its rheumatoid arthritis (RA) drug SPY072 as a standalone…
Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial
Spyre Therapeutics (SYRE) announced results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both doses of SPY072 demonstrated statistically significan...
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo...
Spyre Therapeutics price target raised to $130 from $100 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Spyre Therapeutics (SYRE) to $130 from $100 and keeps an Outperform rating on the shares. In Q2 earnings, the company…
Spyre Therapeutics price target raised to $120 from $90 at Baird
Baird raised the firm’s price target on Spyre Therapeutics (SYRE) to $120 from $90 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results…
Spyre Therapeutics price target raised to $130 from $115 at Guggenheim
Guggenheim raised the firm’s price target on Spyre Therapeutics (SYRE) to $130 from $115 and keeps a Buy rating on the shares. The firm remains “optimistic” that Spyre is “best…
Spyre Therapeutics price target raised to $115 from $90 at Wells Fargo
Wells Fargo raised the firm’s price target on Spyre Therapeutics (SYRE) to $115 from $90 and keeps an Overweight rating on the shares. The firm says positive SPY001/SPY002 data, completed…
Spyre Therapeutics reports Q2 EPS (36c), consensus (75c)
“Following encouraging Phase 2 results from both SPY001 and SPY002, as well as competitor results validating the promise of combination therapy, the case for our approach in IBD has strengthened…
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), demonstrating best-in-class efficacy potential and a safety profile consistent wit...
Spyre Therapeutics Quarterly report: Q2 2026
Spyre Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Spyre Therapeutics Earnings release: Q2 2026
Spyre Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Spyre Therapeutics (SYRE) to Peer Perform from Outperform without a price target The firm believes the shares are trading at fair value on a standalone basis. Spyre…